Norris Perne & French’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.4M Buy
174,343
+491
+0.3% +$57.5K 1.31% 18
2026
Q1
$20.9M Sell
173,852
-78,310
-31% -$9.04M 1.4% 15
2025
Q4
$26.5M Buy
252,162
+28,635
+13% +$2.69M 1.75% 20
2025
Q3
$18.8M Sell
223,527
-36,819
-14% -$3.03M 1.3% 28
2025
Q2
$20.6M Buy
260,346
+2,295
+0.9% +$182K 1.44% 27
2025
Q1
$23.2M Buy
258,051
+2,255
+0.9% +$211K 1.74% 20
2024
Q4
$25.4M Buy
255,796
+909
+0.4% +$93.7K 1.83% 19
2024
Q3
$28.9M Buy
254,887
+51,858
+26% +$6.16M 1.98% 14
2024
Q2
$25.1M Sell
203,029
-687
-0.3% -$88.5K 1.82% 14
2024
Q1
$26.9M Buy
203,716
+548
+0.3% +$67.5K 1.93% 15
2023
Q4
$22.1M Buy
203,168
+29,452
+17% +$3.06M 1.71% 19
2023
Q3
$17.9M Buy
173,716
+1,848
+1% +$199K 1.56% 22
2023
Q2
$19.8M Buy
171,868
+1,340
+0.8% +$152K 1.67% 20
2023
Q1
$18.2M Sell
170,528
-1,275
-0.7% -$138K 1.66% 25
2022
Q4
$19.1M Buy
171,803
+455
+0.3% +$46.5K 1.88% 14
2022
Q3
$14.8M Sell
171,348
-70,408
-29% -$6.29M 1.53% 26
2022
Q2
$22M Sell
241,756
-195
-0.1% -$17.3K 2.12% 9
2022
Q1
$19.9M Sell
241,951
-1,567
-0.6% -$124K 1.6% 21
2021
Q4
$18.7M Sell
243,518
-80,957
-25% -$6.45M 1.45% 28
2021
Q3
$24.4M Buy
324,475
+8,770
+3% +$667K 2.09% 9
2021
Q2
$24.6M Buy
315,705
+35,016
+12% +$2.6M 2.12% 10
2021
Q1
$20.6M Sell
280,689
-5,192
-2% -$383K 1.91% 15
2020
Q4
$22.3M Buy
285,881
+27,194
+11% +$2.08M 2.1% 13
2020
Q3
$20.5M Buy
258,687
+50,007
+24% +$3.92M 2.22% 12
2020
Q2
$15.4M Buy
208,680
+7,972
+4% +$600K 1.87% 20
2020
Q1
$14.7M Buy
200,708
+33,076
+20% +$2.6M 2.21% 12
2019
Q4
$14.5M Buy
167,632
+149
+0.1% +$12.2K 1.74% 19
2019
Q3
$13.5M Buy
167,483
+182
+0.1% +$14.6K 1.68% 19
2019
Q2
$13.4M Buy
167,301
+159
+0.1% +$12.2K 1.69% 21
2019
Q1
$13.3M Buy
167,142
+4,954
+3% +$371K 1.75% 20
2018
Q4
$11.8M Buy
162,188
+1,809
+1% +$128K 1.85% 16
2018
Q3
$10.9M Buy
160,379
+10,030
+7% +$639K 1.42% 30
2018
Q2
$8.71M Buy
150,349
+7,894
+6% +$445K 1.27% 36
2018
Q1
$7.4M Sell
142,455
-524
-0.4% -$28.3K 1.08% 43
2017
Q4
$7.68M Sell
142,979
-2,654
-2% -$147K 1.12% 42
2017
Q3
$8.9M Buy
145,633
+3,709
+3% +$225K 1.39% 26
2017
Q2
$8.68M Buy
141,924
+5,387
+4% +$328K 1.46% 24
2017
Q1
$8.28M Buy
136,537
+1,047
+0.8% +$63.5K 1.55% 17
2016
Q4
$7.61M Buy
135,490
+3,519
+3% +$206K 1.5% 19
2016
Q3
$7.86M Buy
131,971
+3,240
+3% +$189K 1.64% 20
2016
Q2
$7.08M Sell
128,731
-5,653
-4% -$301K 1.53% 23
2016
Q1
$6.79M Buy
134,384
+2,850
+2% +$140K 1.41% 25
2015
Q4
$6.63M Buy
131,534
+21,211
+19% +$1.07M 1.39% 26
2015
Q3
$5.2M Buy
110,323
+30,084
+37% +$1.6M 1.24% 30
2015
Q2
$4.36M Buy
80,239
+3,487
+5% +$196K 0.83% 45
2015
Q1
$4.21M Buy
76,752
+1,411
+2% +$79.9K 0.78% 45
2014
Q4
$4.08M Buy
75,341
+3,897
+5% +$217K 0.75% 47
2014
Q3
$4.04M Buy
71,444
+427
+0.6% +$24K 0.78% 46
2014
Q2
$3.92M Buy
71,017
+949
+1% +$51.8K 0.74% 48
2014
Q1
$3.8M Buy
70,068
+1,271
+2% +$65.8K 0.74% 47
2013
Q4
$3.29M Buy
68,797
+3,041
+5% +$139K 0.62% 50
2013
Q3
$2.99M Buy
65,756
+2,670
+4% +$122K 0.62% 52
2013
Q2
$2.8M Buy
+63,086
New +$2.82M 0.6% 52

Other funds holding MRK

Norris Perne & French's MRK Position: Q2 2026 in Review

Norris Perne & French increased its Merck (MRK) stake by 0.28% in Q2 2026, buying an estimated $57.5K and bringing the position to 174,343 shares worth $22.4M. The position accounts for 1.31% of the portfolio, ranked #18.

Norris Perne & French first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.9M in Q3 2024. 1,533 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Norris Perne & French held 174,343 shares of Merck worth $22.4M as of Q2 2026.
  • Norris Perne & French bought 491 Merck shares in Q2 2026, an estimated $57.5K.
  • Merck made up 1.31% of Norris Perne & French's portfolio in Q2 2026, its #18 holding.
  • Norris Perne & French first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Norris Perne & French's Merck position peaked at $28.9M in Q3 2024.
  • 1,533 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Norris Perne & French's 13F filing for Q2 2026, filed 21 Jul 2026.